Back to Results
First PageMeta Content
Health / Pharmaceuticals policy / Food and Drug Administration / Generic drug / Biosimilar / NIPTE / Test data exclusivity / New Drug Application / Compounding / Pharmaceutical sciences / Pharmacology / Pharmaceutical industry


MAKINGDO INMAKINGDRUGS: INNOVATION POLICYAND PHARMACEUTICALMANUFACTURING
Add to Reading List

Document Date: 2014-03-28 14:07:02

Open Document

File Size: 587,96 KB

Share Result on Facebook

Company

Novartis / GlaxoSmithKline / Research & Dev / PHARMACEUTICAL MANUFACTURING Manufacturing / TEVA PHARM / Boston College Law Review / Manufacturing Processes Pharmaceutical manufacturing / Pharmaceutical Companies / in- 492 Boston College Law Review / INDUST. LTD. / /

Country

United States / Columbia / /

Currency

USD / EUR / /

Event

Product Issues / Product Recall / Debt Financing / FDA Phase / /

IndustryTerm

outdated manufacturing techniques / lower manufacturing costs / manufacturing optimization / allergenic product / slow manufacturing innovation / manufacturing patents / manufacturing process / quality management / food production / analogous product / pioneer manufacturer / absolute manufacturing costs / manufacturing / healthcare costs / modernized manufacturing techniques / drug products / inefficient drug manufacturing / manufacturing problems / manufacturing costs / manufacturing methods / biological product / manufacturing expenses / marketable products / manufacturing innovation parallel / oil industries / manufacturing industry / healthcare system / outdated manufacturing plants / manufacturing innovation / manufacturing lag / manufacturing technique / drug manufacturers / manufacturing advances / manufacturing techniques / Drug manufacturing / marginal manufacturing costs / potato-chip / Patent law / manufacturing innovations / manufacturing process patents / manufacturing plants / potential regulatory solutions / variable manufacturing costs / /

MedicalCondition

additional infections / disease / innovation policy myopia / /

Organization

Petrie-Flom Center / office of Pharm / New England Compounding Center / FDA / Harvard Law School / YALE / Boston College / Graduate School / U.S. Food and Drug Administration / Columbia Law School / FDA’s office of New Drug Quality Assessment / /

Person

Geoff Levitt / Harvey E. Bale Jr. / Henry Grabowski / Ana Bračič / Philip Hamburger / J. Gregory Sidak / Holly Fernandez Lynch / Suzanne Scotchmer / Abbe Gluck / Marc-André Gagnon / Rebecca S. Eisenberg / Kevin Outterson / Lawrence Yu / Hedley Rees / Daniel F. Spulber / Joel Lexchin / Bruce Leicher / Animal Cell / Michael Butler / Irwin I. Park / Brian R. Bouggy / Moheb Nasr / Scott Hensley / Katie Thomas / John Helferich / Betsy Boggs / Margaret R. Taylor / Richard B. Stewart / William E. Ridgway / Ernst R. Berndt / Emil Ciurczak / Innovation / Jeff Skopek / Christopher M. Holman / Girish Malhotra / Ron A. Bouchard / Jordan Paradise / Ajaz Hussain / I. Glenn Cohen / Bob A. Rappaport / Wesley A. Magat / Ben Roin / Thomas Friedli / Jennifer S. Bard / Leila Abboud / Agnes Shanley / Animal Cell Cultures / Joanne Eglovitch / /

Position

Vice President of Regulatory Chemistry and Manufacturing Controls Strategy / Director / Senior Vice President / Butler / /

Product

Eryn Brown / propofol / Drug / Excedrin / science-based understanding / tablets / Causal Links / batches / /

ProvinceOrState

Michigan / Missouri / California / /

PublishedMedium

Boston College Law Review / /

RadioStation

85 AM / /

Technology

Biopharmaceuticals / drug discovery / Biotechnology / http / simulation / Drug Development / /

URL

http /

SocialTag